No Prescription |
 |
 | ||
|
Lamictal DC Generic Lamotrigine |
|
| ||
No Prescription » Prescription Drugs 9 » Lamictal DC Generic Lamotrigine Lamotrigine is used alone or with other medications to prevent or control seizures (epilepsy) in people aged 2 and older. It may also be used to help prevent the extreme mood swings of bipolar disorder in people aged 18 and older.This medication is an anticonvulsant. Lamotrigine is thought to work by restoring the balance of certain natural substances (neurotransmitters) in the brain. Buy Lamictal DC Generic Lamotrigine and other Prescription Drugs 9 products online at Medstore. Buy Online at Medstore - Click Here!
About Lamictal DC Generic Lamotrigine: Product Type: Prescription Drugs 9 Lamictal DC ( Generic Lamotrigine ) Lamictal DC (Generic Lamotrigine) Generic Lamotrigine 100mg Generic Lamotrigine Lamictal DC
View more Prescription Drugs 9 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
